<DOC>
	<DOCNO>NCT01942460</DOCNO>
	<brief_summary>The purpose study investigate efficacy ferumoxytol repletion iron store correction iron deficiency anaemia patient severe chronic kidney disease end-stage chronic kidney disease peritoneal dialysis , assess impact administration ferumoxytol dose various marker iron store , well various marker inflammation oxidative stress .</brief_summary>
	<brief_title>Ferumoxytol Iron-Deficiency Anemia Chronic Kidney Disease Peritoneal Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>For woman childbearing age , negative serum pregnancy test screening . Severe chronic kidney disease ( TFGe low 30 ml/min ) OR endstage kidney disease peritoneal dialysis . Anaemia , define haemoglobin ( Hb ) &lt; 120 g/L , within 14 day prior screen , patient without Erythropoiesisstimulating agent ( ESA ) . Iron depletion , define transferrin saturation ( TSAT ) &lt; 20 % and/or ferritin assay ( FERR ) &lt; 200 , within 14 day prior screen . If ESA use , stable dose past 60 day . Allergy ferumoxytol another intravenous iron formulation . Administration ferumoxytol intravenous , intramuscular oral iron formulation within 30 day enrolment . Patient receive blood transfusion within 2 week prior enrolment , plan receive blood transfusion duration study . Patient currently participate clinical trial another investigational drug device receive investigational drug device within 30 day enrolment study . Hb &lt; 90 g/L time screen . Existing clinically suspect bleed digestive , gynaecological origin . Patient another cause anemia , iron deficiency ( example , limited , systemic lupus erythematosus , rheumatoid arthritis , multiple myeloma , myelodysplastic disorder , etc. ) . Patients respond ESA receive excess 30000 units/week erythropoietin ( EPO ) , 150 mcg/week darbepoietin alfa . Major surgery within one month prior enrolment study plan surgery , vascular access creation , patient study . Patient malignancy ( except nonmelanoma cancer skin ) unless patient receive curative treatment diseasefree &gt; 2 year . Patient consider Investigator medical status would preclude patient 's participation protocol . Patient due magnetic resonance image examination examination plan , next three month . Woman plan become pregnant next three month . Woman breastfeed . Ongoing recent ( &lt; 2 week ) bacterial infection require treatment . Patient unable give inform consent . Patient refuse give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Iron</keyword>
	<keyword>Anemia</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Peritoneal Dialysis</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Oxidative stress</keyword>
</DOC>